Ulcer disease
diseaseOn this page
Also known as ulcerulcers
Summary
Ulcer disease (MONDO:0043839) is a disease and 99 clinical trials. Top therapeutic interventions include collagenase clostridium histolyticum, esomeprazole, and acyclovir. A subtype of disease by developmental or physiological process — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 99
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ulcer disease |
| Mondo ID | MONDO:0043839 |
| MeSH | D014456 |
| NCIT | C3426 |
| SNOMED CT | 429040005 |
| UMLS | C0041582 |
| MedGen | 22541 |
| Is cancer (heuristic) | no |
Also known as: ulcer · ulcers
Disease family
An umbrella term covering 3 Mondo subtypes.
Classification path: disease › human disease › disease by developmental or physiological process › ulcer disease
Related subtypes (11): psychiatric disorder, metabolic disease, premature aging syndrome, disorder of development or morphogenesis, inflammatory disease, disorder of glycosylation, mitochondrial disease, sleep disorder, perinatal disease, obstetric disorder, disease by molecular mechanism
Subtypes (3): peptic ulcer disease, corneal ulcer, esophageal ulcer
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
3 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Collagenase Clostridium Histolyticum | Approved (phase 4) |
| Dimethicone | Approved (phase 4) |
| Famotidine | Approved (phase 4) |
| Becaplermin | Phase 3 (in late-stage trials) |
| Bosentan | Phase 3 (in late-stage trials) |
| Cimetidine | Phase 3 (in late-stage trials) |
| Esomeprazole | Phase 3 (in late-stage trials) |
| Macitentan | Phase 3 (in late-stage trials) |
| Oxygen | Phase 3 (in late-stage trials) |
| Pantoprazole | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Isoniazid, Omeprazole, Onabotulinumtoxina, Riociguat.
Clinical trials & evidence
Clinical trials
Clinical trials: 99.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 58 |
| PHASE4 | 11 |
| PHASE3 | 10 |
| PHASE2 | 9 |
| PHASE1 | 5 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06826339 | PHASE4 | RECRUITING | Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers. |
| NCT06999590 | PHASE4 | RECRUITING | Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers |
| NCT07086443 | PHASE4 | RECRUITING | Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy |
| NCT07089602 | PHASE4 | RECRUITING | Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers |
| NCT07255391 | PHASE4 | ENROLLING_BY_INVITATION | Use of PRP for the Healing of Grade III Ulcers |
| NCT07364630 | PHASE4 | RECRUITING | A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers. |
| NCT00363701 | PHASE4 | UNKNOWN | Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice |
| NCT00633035 | PHASE4 | COMPLETED | Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit |
| NCT00813631 | PHASE4 | UNKNOWN | The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound |
| NCT00926809 | PHASE4 | UNKNOWN | H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection |
| NCT03823963 | PHASE4 | UNKNOWN | Study on Pressure Ulcers Prevention With Mepilex® Border Sacrum Dressing in Scheduled Cardiovascular Surgery |
| NCT00164424 | PHASE2/PHASE3 | COMPLETED | Episodic Acyclovir Therapy for Genital Ulcers |
| NCT00402727 | PHASE3 | COMPLETED | Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection |
| NCT00450216 | PHASE3 | COMPLETED | Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment |
| NCT00701974 | PHASE2/PHASE3 | SUSPENDED | Non-inferiority Clinic of Kollagenase® Compared Iruxol® in Treatment of Cutaneous Ulcers |
| NCT00979836 | PHASE3 | SUSPENDED | Calcium Dobesilate for Chronic Venous Wounds |
| NCT01214811 | PHASE3 | COMPLETED | Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing |
| NCT01474109 | PHASE3 | COMPLETED | Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients |
| NCT01853384 | PHASE3 | TERMINATED | Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers |
| NCT02213952 | PHASE3 | WITHDRAWN | PRP ULCERAS: Clinical Trial Phase III |
| NCT02286427 | PHASE3 | UNKNOWN | A Comparative Study of the Healing of Chronic Ulcers of Recessive Epidermolysis Bullosa : Dressing vs Amniotic Membrane |
| NCT04274049 | PHASE3 | COMPLETED | Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2) |
| NCT04275323 | PHASE3 | COMPLETED | Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1) |
| NCT00061633 | PHASE2 | COMPLETED | Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) |
| NCT00158483 | PHASE2 | COMPLETED | Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212) |
| NCT00189540 | PHASE2 | COMPLETED | Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers |
| NCT00221143 | PHASE1/PHASE2 | COMPLETED | Stem Cell Study for Patients With Leg Ulcer/Gangrene |
| NCT00368602 | PHASE2 | TERMINATED | Beta Blocker for Chronic Wound Healing |
| NCT00597818 | PHASE2 | COMPLETED | Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury |
| NCT01138436 | PHASE2 | COMPLETED | A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Venous Leg Ulcers |
| NCT01548378 | PHASE2 | COMPLETED | Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia |
| NCT01770509 | PHASE1/PHASE2 | COMPLETED | The Effect of the Cosmetic Cream NMBM on Leg Ulcers - a Pilot Study |
| NCT01817218 | PHASE1/PHASE2 | COMPLETED | Feasibility and Safety and Evaluation of the Potential Efficacy of Autologous Platelet-rich Plasma in the Treatment of Vascular Venous Ulcers |
| NCT02395042 | PHASE2 | COMPLETED | A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner’s Lesions |
| NCT02973893 | PHASE2 | UNKNOWN | Study of VF001-DP in Patients With Chronic Venous Leg Ulcers |
| NCT00688428 | PHASE1 | COMPLETED | Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination |
| NCT02319720 | PHASE1 | TERMINATED | Study to Evaluate Bone Marrow Cells in the Treatment of Chronic Wounds |
| NCT03026855 | PHASE1 | COMPLETED | Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers |
| NCT04134676 | PHASE1 | COMPLETED | Therapeutic Potential of Stem Cell Conditioned Medium on Chronic Ulcer Wounds |
| NCT04963829 | PHASE1 | COMPLETED | Unripe Banana Peel Powder and Lemongrass Oil in Chronic Ulcer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| COLLAGENASE CLOSTRIDIUM HISTOLYTICUM | 4 | 3 |
| ESOMEPRAZOLE | 4 | 3 |
| ACYCLOVIR | 4 | 2 |
| FAMOTIDINE | 4 | 2 |
| AMOXICILLIN | 4 | 1 |
| CLARITHROMYCIN | 4 | 1 |
| CLAVULANIC ACID | 4 | 1 |
| MACITENTAN | 4 | 1 |
| PIPERACILLIN | 4 | 1 |
| TELAVANCIN | 4 | 1 |
| TIMOLOL MALEATE | 4 | 1 |
| CALCIUM DOBESILATE | 3 | 1 |
| OZONE | 3 | 1 |
| BUCRYLATE | 2 | 1 |
| COBIPROSTONE | 2 | 1 |
| CHEMBL4802121 | 0 | 1 |
| CHEMBL5271499 | 0 | 1 |
| SNAP (S-NITROSO-N-ACETYLPENICILLAMINE) | 0 | 1 |